# Jessica Grossman

> Jessica Grossman, M.D., is a physician-turned-inventor, founder and biotechnology executive who leads IgGenix, a clinical-stage antibody discovery and development company. Her career has moved through women’s-health medical devices, a successfully acquired remote-monitoring startup, nonprofit pharmaceuticals and now allergen-specific antibody development, with a consistent focus on translating research into products and building organizations around practical patient impact.

- **Role:** Chief Executive Officer at IgGenix, Inc.
- **Organizations:** IgGenix, Inc., Daré Bioscience, Inc., Medicines360, Sense4Baby, Inc., Gynesonics, Inc., Ethicon Endo-Surgery, JG Limited LLC
- **Education:** B.A. in Biology and English, with honors, Brandeis University, M.D., Thomas Jefferson University, Jefferson Medical College
- **Known for:** Founded Gynesonics and raised its first two rounds of venture financing., Led Sense4Baby through a Series A financing and a successful acquisition after regulatory clearance and commercialization milestones., As CEO of Medicines360, increased revenue by 200% and raised $20 million in non-dilutive capital.

## Career timeline

- **2005-2008** — Founded Gynesonics and served as president, developing the company’s early strategy and raising its first two venture rounds.
- **2008-2010** — Founded and led JG Limited LLC, advising medical-technology companies and nonprofit organizations on clinical and commercial strategy.
- **2010-2013** — Served as medical director at Ethicon Endo-Surgery, part of Johnson & Johnson.
- **2013-2014** — Served as founding president and CEO of Sense4Baby, raised a Series A round and led the company to acquisition.
- **2015-2020** — Served as CEO of Medicines360, a nonprofit pharmaceutical company; increased revenue by 200% and raised $20 million in non-dilutive capital.
- **2018-present** — Serves on the board of directors of Daré Bioscience.
- **2020-present** — Leads IgGenix as CEO, advancing its antibody discovery platform and lead program into clinical development.
- **2023** — IgGenix announced the first close of a $40 million Series B financing.
- **2024** — IgGenix dosed the first participant in the Phase 1 ACCELERATE Peanut trial for IGNX001.
- **2025** — IgGenix completed enrollment in the Phase 1 ACCELERATE Peanut trial.

## Achievements

- Founded Gynesonics and raised its first two rounds of venture financing.
- Led Sense4Baby through a Series A financing and a successful acquisition after regulatory clearance and commercialization milestones.
- As CEO of Medicines360, increased revenue by 200% and raised $20 million in non-dilutive capital.
- Led IgGenix through more than $60 million in venture capital raised during her tenure and into clinical-stage development.
- Named among Becker’s Hospital Review’s 110 women in medtech to know in 2017.
- Credited with 11 issued patents in corporate biographies and has authored peer-reviewed publications.
- Has served as an independent director of Daré Bioscience since April 2018.

## Latest updates

- **2026-06** — Grossman spoke on patient-centricity at a Longwood Healthcare Leaders event connected with MIT’s biotech ecosystem.
- **2026-02** — She promoted IgGenix’s IGNX001 program and discovery platform around the 2026 AAAAI annual meeting.
- **2025-11** — Marking five years at IgGenix, she wrote that the company had grown from an early idea into a clinical-stage organization with a lead program in the clinic.
- **2025-09** — IgGenix announced completion of enrollment in its Phase 1 ACCELERATE Peanut trial, and Grossman credited the team, investigators, participants and families.
- **2025-02** — IgGenix presented monoclonal-antibody discovery work at the 2025 AAAAI / WAO Joint Congress.

## Links

- Website: https://iggenix.com
- LinkedIn: https://www.linkedin.com/in/jessica-grossman-md-ba7019b
- Twitter/X: https://twitter.com/IgGenix

---

Profile page: https://yespress.io/jessica-grossman
Published by YesPress — https://yespress.io
Last updated: 2026-08-18